期刊
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
卷 193, 期 1, 页码 3-12出版社
WILEY
DOI: 10.1111/cei.13101
关键词
arthritis (including rheumatoid arthritis); autoinflammatory disease; genomics; inflammation; systemic lupus erythematosus
类别
资金
- NIHR Manchester BRC
- Arthritis Research UK [20385]
- MRC [MR/K015346/1] Funding Source: UKRI
- Medical Research Council [MR/K015346/1] Funding Source: researchfish
- National Institute for Health Research [ACF-2013-06-011, NF-SI-0515-10034] Funding Source: researchfish
Immune-mediated inflammatory diseases (IMIDs) are characterized by dysregulation of the normal immune response, which leads to inflammation. Together, they account for a high disease burden in the population, given that they are usually chronic conditions with associated co-morbidities. Examples include systemic lupus erythematosus, rheumatoid arthritis, Crohn's disease and type 1 diabetes. Since the advent of genome-wide association studies, evidence of considerable genetic overlap in the loci predisposing to a wide range of IMIDs has emerged. Understanding the genetic risk and extent of genetic overlap between IMIDs may help to determine which genes control which aspects of the different diseases; it may identify potential novel therapeutic targets for a number of these conditions, and/or it may facilitate repurposing existing therapies developed originally for different conditions. The findings show that autoantibody-mediated autoimmune diseases cluster more closely with each other than autoantibody-negative diseases such as psoriasis, psoriatic arthritis, Crohn's disease and ankylosing spondylitis which, instead, form a seronegative genetic cluster. The genetic clustering largely mirrors the known response to existing biological therapies, but apparent anomalies in treatment response are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据